VERAXA Biotech (NASDAQ: VRXA) announced an expansion of its intellectual property portfolio, filing new patent applications during the first half of 2026 covering its next-generation BiTAC-TCE and BiTAC-ADC technology platforms and related therapeutic programs. The company said previously granted patents protecting supporting technologies have also cleared the opposition period, bringing its portfolio to more than 50 granted owned or exclusively licensed patents across 14 countries and 26 patent families. Pending approval of the latest filings, VERAXA expects its core technologies to be protected through at least 2047.
The BiTAC platform is designed to improve the selectivity and safety of cancer therapies by activating treatments only when multiple tumor-associated targets are present, potentially reducing off-target effects common in conventional cancer treatments. VERAXA also highlighted proprietary click chemistry, conjugation, linker and payload technologies intended to enhance the safety, efficacy and manufacturability of its antibody-drug conjugate and T-cell engager pipelines, reinforcing its long-term strategy to develop next-generation oncology therapeutics.
This patent expansion comes as VERAXA continues to advance its pipeline of ADCs and proprietary BiTAC formats into clinical development. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.
For more details, the full press release is available at https://ibn.fm/BqhFS. The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA.
Forward-looking statements in this article involve risks and uncertainties, including those set forth under "Risk Factors" in the Company's SEC filings. Undue reliance should not be placed on forward-looking statements, which are based on information available on the date hereof. All parties undertake no duty to update this information unless required by law.
